Curcumin: An effective inhibitor of interleukin-6

Current Pharmaceutical Design

Volumn 23, Issue 6, 2017, Pages 921-931

  Ghandadi, Morteza ^a   Sahebkar, Amirhossein ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Curcumin; IL 6; Inflammation; NF B

Indexed keywords

ACUTE PHASE PROTEIN; AUTOANTIBODY; CELL ADHESION MOLECULE; CHEMOKINE; CURCUMIN; CYTOKINE; INTERLEUKIN 6; MICRORNA;

ANGIOGENESIS; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE DIFFERENTIATION; BLOOD VESSEL PERMEABILITY; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; HEMATOPOIESIS; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CURCUMIN; HUMANS; INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 85017532473     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161006151605     Document Type: Review

References (153)

1. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol 2015; 83: 111-24.
2. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141-53.
3. Panahi Y, Sahebkar A, Amiri M, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebocontrolled trial. Br J Nutr 2012; 108: 1272-9.
4. Sahebkar A, Mohammadi A, Atabati A, et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 2013; 27: 1883-8.
5. Padmanaban G, Rangarajan PN. Curcumin as an adjunct drug for infectious diseases. Trends Pharmacol Sci 2016; 37: 1-3.
6. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17: 190-7.
7. Zingg JM, Hasan ST, Meydani M. Molecular mechanisms of hypolipidemic effects of curcumin. Biofactors 2013; 39: 101-21.
8. Sahebkar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant-antioxidant mechanisms. Nat Prod Res 2015; 29: 491-2.
9. Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoidspiperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 2014; 22: 851-7.
10. Sahebkar A. Low-density lipoprotein is a potential target for curcumin: novel mechanistic insights. Basic Clin Pharmacol Toxicol 2014; 114: 437-8.
11. Sahebkar A. Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 2014; 11: 123.
12. Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 2013; 27: 374-9.
13. Sahebkar A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 2013; 39: 197-208.
14. Sahebkar A. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 2010; 94: e75-6; author reply e77.
15. Hu S, Maiti P, Ma Q, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 2015; 15: 629-37.
16. Panahi Y, Ghanei M, Hajhashemi A, Sahebkar A. Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: A randomized controlled trial. J Diet Suppl 2016; 13: 93-105.
17. Sahebkar A. Autophagic activation: A key piece of the puzzle for the curcumin-associated cognitive enhancement? J Psychopharmacol 2016; 30: 93-4.
18. Shakeri A, Sahebkar A. Optimized curcumin formulations for the treatment of Alzheimer's disease: A patent evaluation. J Neurosci Res 2015; 131(4): e29-322.
19. Esmaily H, Sahebkar A, Iranshahi M, et al. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin J Integr Med 2015; 21: 332-8.
20. Panahi Y, Badeli R, Karami GR, Sahebkar A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother Res 2015; 29: 17-21.
21. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a randomized controlled trial. J Diet Suppl 2016; 13: 209-20.
22. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1625-31.
23. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets 2011; 12: 332-47.
24. Miki C, Inoue Y, Araki T, Uchida K, Kusunoki M. Cytokines and cancer development. J Surg Oncol 2007; 95: 10-11.
25. Azuma MM, Samuel RO, Gomes-Filho JE, Dezan-Junior E, Cintra LT. The role of IL-6 on apical periodontitis: a systematic review. Int Endod J 2014; 47: 615-21.
26. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
27. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
28. Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013; 40: 336-43.
29. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
30. Hirano T, Taga T, Yasukawa K, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A 1987; 84: 228-31.
31. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. BioMed Res Int 2014; 2014.
32. van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an antiinterleukin- 6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015; 6: 30408-19.
33. Rosean TR, Tompkins VS, Tricot G, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res 2014; 59: 188-202.
34. Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int 2014; 113: 986-92.
35. Kaminska K, Czarnecka AM, Escudier B, Lian F, Szczylik C. Interleukin-6 as an emerging regulator of renal cell cancer. Urol Oncol 2015; 33: 476-85.
36. Lesina M, Wormann SM, Neuhofer P, Song L, Algul H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol 2014; 26: 80-7.
37. Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013; 138: 657-64.
38. Abdollahi E, Momtazi AA, Johnston TP, Sahebkar A. Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jack-of-all-trades? J Cell Physiol 2017; doi: 10.1002/jcp.25778.[Epub ahead of print].
39. Dale RC. Interleukin-6 blockade as rescue therapy in autoimmune encephalitis. Neurotherapeutics 2016; 13: 821-3.
40. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Letters 2011; 585: 3699-3709.
41. Ohtsuji M, Lin Q, Nishikawa K, et al. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcgammaRIIB-deficient rheumatoid arthritis mouse model. Mod Rheumatol 2015; 25: 270-7.
42. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002; 20: 304-11.
43. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel antiinterleukin- 6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28: 3701-8.
44. Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-9.
45. Mao X, Wu Y, Diao H, et al. Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model. Clin Rheumatol 2014; 33: 1585-93.
46. Cash H, Relle M, Menke J, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 2010; 37: 60-70.
47. Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012; 180: 165-76.
48. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin- 17A. Arthritis Rheum 2009; 60: 2505-12.
49. Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52: 3264-71.
50. Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008; 105: 9041-6.
51. Song L, Smith MA, Doshi P, et al. Antitumor efficacy of the antiinterleukin- 6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol 2014; 9: 974-82.
52. Savvatis K, Müller I, Fröhlich M, et al. Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis. Basic Res Cardiol 2014; 109: 1-14.
53. Yamaguchi K, Nishimura T, Ishiba H, et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high‐fat diet fed mice. Liver Int 2015; 35: 550-61.
54. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti–IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease. Clin Cancer Res 2013; 19: 3659-70.
55. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern Rheumatol 2013; 23: 827-31.
56. Suzuki K, Ogura M, Abe Y, et al. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/ refractory multiple myeloma. Int J Hematol 2015; 101: 286-94.
57. Briot K, Rouanet S, Schaeverbeke T, et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 2015; 82: 109-15.
58. Semerano L, Thiolat A, Minichiello E, Clavel G, Bessis N, Boissier MC. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Expert Opin Investig Drugs 2014; 23: 979-99.
59. Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab - the role of anti-interleukin-6 therapy after a decade of treatment. Biol Therapy 2012; 2: 1.
60. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 118-28.
61. Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J 2012; 21: 2079-84.
62. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
63. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-96; discussion 947.
64. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011; 10: 12.
65. Zhou H, Beevers CS, Huang S. Targets of curcumin. Current drug targets 2011; 12: 332-347.
66. Ruan M, Thorn K, Liu S, Li S, Yang W, Zhang C. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma. Int J Oncol 2014; 44: 2103-10.
67. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH. Curcumin blocks the activation of androgen and interlukin-6 on prostatespecific antigen expression in human prostatic carcinoma cells. J Androl 2008; 29: 661-8.
68. Du Y, Long Q, Zhang L, et al. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/ HIF-1alpha signaling. Int J Oncol 2015; 47: 2064-72.
69. Hendrayani S-F, Al-Khalaf HH, Aboussekhra A. Curcumin triggers p16-dependent senescence in active breast cancer-associated fibroblasts and suppresses their paracrine procarcinogenic effects. Neoplasia (New York, N.Y.) 2013; 15: 631-40.
70. Singh M, Ramos I, Asafu-Adjei D, et al. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med 2013; 2: 571-82.
71. Lu Y, Miao L, Wang Y, et al. Curcumin micelles remodel tumor microenvironment and enhance vaccine activity in an advanced melanoma model. Mol Ther 2016; 24: 364-74.
72. Cohen AN, Veena MS, Srivatsan ES, Wang MB. Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 2009; 135: 190-7.
73. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticleencapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 2007; 5: 3-3.
74. Park J, Ayyappan V, Bae EK, et al. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008; 2: 317-26.
75. Yang C-L, Liu Y-Y, Ma Y-G, et al. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through janus kinase-STAT3 signalling pathway. PLoS One 2012; 7: e37960.
76. Chakravarti N, Myers JN, Aggarwal BB. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006; 119: 1268-75.
77. Das L, Vinayak M. Long-term effect of curcumin down-regulates expression of tumor necrosis factor-alpha and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-kappaB transcription factors in livers of lymphoma bearing mice. Leuk Lymphoma 2014; 55: 2627-36.
78. Moriasi CM, Trevino C, Subramaniam D, et al. Curcumin regulates Interleukin-6 expression in colon cancer cells. Cancer Res 2011; 71: 4606.
79. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prevent Res 2012; 5: 205-15.
80. Seo JH, Jeong KJ, Oh WJ, et al. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 2010; 288: 50-6.
81. Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 2003; 194: 63-70.
82. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70: 700-13.
83. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 2004; 111: 679-92.
84. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-62.
85. Bordoloi D, Roy NK, Monisha J, Ganesan P, Kunnumakkara AB. Multi-targeted agents in cancer cell chemosensitization: what we learnt from curcumin thus far. Recent Pat Anticancer Drug Discov 2016; 11: 67-97.
86. Ghandadi M, Sahebkar A. Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. Curr Pharm Des 2016; 22: 518-26.
87. Deguchi A. Curcumin targets in inflammation and cancer. Endocr Metab Immune Disord Drug Targets 2015; 15: 88-96.
88. Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemotherapy 2013; 40: 336-343.
89. Panahi Y, Ghanei M, Bashiri S, Hajihashemi A, Sahebkar A. Shortterm curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. Drug Res (Stuttg) 2015; 65: 567-73.
90. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009; 9: 575-81.
91. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002; 168: 6506-13.
92. Kloesch B, Becker T, Dietersdorfer E, Kiener H, Steiner G. Antiinflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes. Int Immunopharmacol 2013; 15: 400-5.
93. Shing CM, Adams MJ, Fassett RG, Coombes JS. Nutritional compounds influence tissue factor expression and inflammation of chronic kidney disease patients in vitro. Nutrition 2011; 27: 967-72.
94. Jin W, Wang J, Zhu T, et al. Anti-inflammatory effects of curcumin in experimental spinal cord injury in rats. Inflamm Res 2014; 63: 381-7.
95. Ni H, Jin W, Zhu T, et al. Curcumin modulates TLR4/NF-kappaB inflammatory signaling pathway following traumatic spinal cord injury in rats. J Spinal Cord Med 2015; 38: 199-206.
96. Wang NP, Pang XF, Zhang LH, Tootle S, Harmouche S, Zhao ZQ. Attenuation of inflammatory response and reduction in infarct size by postconditioning are associated with down-regulation of early growth response 1 during reperfusion in rat heart. Shock 2014; 41: 346-54.
97. Zhou T, Chen D, Li Q, Sun X, Song Y, Wang C. Curcumin inhibits inflammatory response and bone loss during experimental periodontitis in rats. Acta Odontol Scand 2013; 71: 349-56.
98. Hasan ST, Zingg JM, Kwan P, Noble T, Smith D, Meydani M. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis 2014; 232: 40-51.
99. Avasarala S, Zhang F, Liu G, Wang R, London SD, London L. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLoS One 2013; 8: e57285.
100. Huang G, Xu Z, Huang Y, et al. Curcumin protects against collagen-induced arthritis via suppression of BAFF production. J Clin Immunol 2013; 33: 550-7.
101. Tu CT, Han B, Liu HC, Zhang SC. Curcumin protects mice against concanavalin A-induced hepatitis by inhibiting intrahepatic intercellular adhesion molecule-1 (ICAM-1) and CXCL10 expression. Mol Cell Biochem 2011; 358: 53-60.
102. Wang Y, Li J, Zhuge LI, et al. Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet. Exp Therap Med 2014; 7: 663-8.
103. Gukovsky I, Reyes CN, Vaquero EC, Gukovskaya AS, Pandol SJ. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G85-95.
104. Zhong K. Curcumin mediates a protective effect via TLR-4/NF-κB signaling pathway in rat model of severe acute pancreatitis. Cell Biochem Biophys 2015; 73(1): 175-80.
105. Song Y, Ge W, Cai H, Zhang H. Curcumin protects mice from coxsackievirus B3-induced myocarditis by inhibiting the phosphatidylinositol 3 kinase/Akt/nuclear factor-kappaB pathway. J Cardiovasc Pharmacol Ther 2013; 18: 560-9.
106. Ali SO, Darwish HA, Ismail NA. Curcumin, silybin-phytosome and alpha-R-lipoic acid mitigate chronic hepatitis in rat by inhibiting oxidative stress and inflammatory cytokines production. Basic Clin Pharmacol Toxicol 2016; 118: 369-80.
107. Gulcubuk A, Haktanir D, Cakiris A, et al. Effects of curcumin on pro-inflammatory cytokines and tissue injury in the early and late phases of experimental acute pancreatitis. Pancreatology 2013; 13: 347-54.
108. Kim J, Jeong SW, Quan H, Jeong CW, Choi JI, Bae HB. Effect of curcumin (Curcuma longa extract) on LPS-induced acute lung injury is mediated by the activation of AMPK. J Anesth 2016; 30: 100-8.
109. Sandersen C, Bienzle D, Cerri S, et al. Effect of inhaled hydrosoluble curcumin on inflammatory markers in bronchoalveolar lavage fluid of horses with LPS-induced lung neutrophilia. Multidisciplinary Respir Med 2015; 10: 16.
110. Tu CT, Yao QY, Xu BL, et al. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem Toxicol 2012; 50: 3343-51.
111. Wu SJ, Tam KW, Tsai YH, Chang CC, Chao JC. Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats. Am J Chin Med 2010; 38: 99-111.
112. Seehofer D, Schirmeier A, Bengmark S, et al. Curcumin attenuates oxidative stress and inflammatory response in the early phase after partial hepatectomy with simultaneous intraabdominal infection in rats. J Surg Res 2010; 159: 497-502.
113. Kadasa NM, Abdallah H, Afifi M, Gowayed S. Hepatoprotective effects of curcumin against diethyl nitrosamine induced hepatotoxicity in albino rats. Asian Pac J Cancer Prev 2015; 16: 103-8.
114. Fu Y, Gao R, Cao Y, et al. Curcumin attenuates inflammatory responses by suppressing TLR4-mediated NF-kappaB signaling pathway in lipopolysaccharide-induced mastitis in mice. Int Immunopharmacol 2014; 20: 54-8.
115. Klawitter M, Quero L, Klasen J, et al. Curcuma DMSO extracts and curcumin exhibit an anti-inflammatory and anti-catabolic effect on human intervertebral disc cells, possibly by influencing TLR2 expression and JNK activity. J Inflamm (London, England) 2012; 9: 29.
116. Guimarães MR, Leite FRM, Spolidorio LC, Kirkwood KL, Rossa C. Curcumin abrogates LPS-induced pro-inflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1, -3 and p38 MAPK. Arch Oral Biol 2013; 58: 1309-17.
117. Liu L, Shang Y, Li M, Han X, Wang J. Curcumin ameliorates asthmatic airway inflammation by activating nuclear factor-E2- related factor 2/haem oxygenase (HO)-1 signalling pathway. Clin Exp Pharmacol Physiol 2015; 42: 520-9.
118. Zhao F, Gong Y, Hu Y, et al. Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide: translocation of nuclear factor-kappaB as potential target. Mol Med Rep 2015; 11: 3087-93.
119. Chen FY, Zhou J, Guo N, et al. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun 2015; 467: 872-8.
120. Kaur H, Patro I, Tikoo K, Sandhir R. Curcumin attenuates inflammatory response and cognitive deficits in experimental model of chronic epilepsy. Neurochem Int 2015; 89: 40-50.
121. Jin CY, Lee JD, Park C, Choi Yh, Kim GY. Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharidestimulated BV2 microglia. Acta Pharmacol Sin 2007; 28: 1645-51.
122. Antoine F, Simard JC, Girard D. Curcumin inhibits agent-induced human neutrophil functions in vitro and lipopolysaccharideinduced neutrophilic infiltration in vivo. Int Immunopharmacol 2013; 17: 1101-7.
123. Sun J, Zhao Y, Hu J. Curcumin Inhibits Imiquimod-Induced Psoriasis-Like Inflammation by Inhibiting IL-1beta and IL-6 Production in Mice. PLoS One 2013; 8: e67078.
124. Sun J, Zhao Y, Jin H, Hu J. Curcumin relieves TPA-induced Th1 inflammation in K14-VEGF transgenic mice. Int Immunopharmacol 2015; 25: 235-41.
125. Radeff-Huang J, Seasholtz TM, Chang JW, Smith JM, Walsh CT, Brown JH. Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression. J Biol Chem 2007; 282: 863-70.
126. Liu X, Liu M, Yuan W, et al. Anti–viral effects of curcumin on influenza A virus–induced myocarditis via inhibiting Wnt/β– catenin signaling. Central Eur J Immunol 2013; 38: 328-35.
127. Tuorkey M, Karolin K. Anti-ulcer activity of curcumin on experimental gastric ulcer in rats and its effect on oxidative stress/antioxidant, IL-6 and enzyme activities. Biomed Environ Sci 2009; 22: 488-95.
128. Zhang N, Li H, Jia J, He M. Anti-inflammatory effect of curcumin on mast cell-mediated allergic responses in ovalbumin-induced allergic rhinitis mouse. Cell Immunol 2015; 298: 88-95.
129. King MD, McCracken DJ, Wade MF, Meiler SE, Alleyne CH, Dhandapani KM. Curcumin attenuates hematoma size and neurological injury following intracerebral hemorrhage in mice. J Neurosurg 2011; 115: 116-23.
130. Davis JM, Murphy EA, Carmichael MD, et al. Curcumin effects on inflammation and performance recovery following eccentric exercise-induced muscle damage. Am J Physiol Regul Integr Comp Physiol 2007; 292: R2168-73.
131. Li Y, Li J, Li S, et al. Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol Appl Pharmacol 2015; 286: 53-63.
132. Abo-Salem OM, Harisa GI, Ali TM, El-Sayed el SM, Abou-Elnour FM. Curcumin ameliorates streptozotocin-induced heart injury in rats. J Biochem Mol Toxicol 2014; 28: 263-70.
133. Yang MW, Wang TH, Yan PP, et al. Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine 2011; 18: 205-13.
134. Singh AK, Vinayak M. Curcumin attenuates CFA induced thermal hyperalgesia by modulation of antioxidant enzymes and down regulation of TNF-alpha, IL-1beta and IL-6. Neurochem Res 2015; 40: 463-72.
135. Okunieff P, Xu J, Hu D, et al. Curcumin protects against radiationinduced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. Int J Radiat Oncol Biol Phys 2006; 65: 890-8.
136. Fan Z, Jing H, Yao J, et al. The protective effects of curcumin on experimental acute liver lesion induced by intestinal ischemiareperfusion through inhibiting the pathway of NF-κB in a rat model. Oxidat Med Cell Longevity 2014; 2014: 191624.
137. Karatepe O, Gulcicek OB, Ugurlucan M, et al. Curcumin nutrition for the prevention of mesenteric ischemia-reperfusion injury: an experimental rodent model. Transplant Proc 2009; 41: 3611-6.
138. Fan Z, Yao J, Li Y, Hu X, Shao H, Tian X. Anti-inflammatory and antioxidant effects of curcumin on acute lung injury in a rodent model of intestinal ischemia reperfusion by inhibiting the pathway of NF-Kb. Int J Clin Exp Pathol 2015; 8: 3451-9.
139. Alghasham A, Salem TA, Meki AR. Effect of cadmium-polluted water on plasma levels of tumor necrosis factor-alpha, interleukin-6 and oxidative status biomarkers in rats: protective effect of curcumin. Food Chem Toxicol 2013; 59: 160-4.
140. Rennolds J, Malireddy S, Hassan F, et al. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Biochem Biophys Res Commun 2012; 417: 256-61.
141. Lim R, Barker G, Wall CA, Lappas M. Dietary phytophenols curcumin, naringenin and apigenin reduce infection-induced inflammatory and contractile pathways in human placenta, foetal membranes and myometrium. Mol Hum Reprod 2013; 19: 451-62.
142. Devi YS, DeVine M, DeKuiper J, Ferguson S, Fazleabas AT. Inhibition of IL-6 signaling pathway by curcumin in uterine decidual cells. PLoS One 2015; 10: e0125627.
143. Ferreira VH, Nazli A, Dizzell SE, Mueller K, Kaushic C. The antiinflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. PLoS One 2015; 10: e0124903.
144. Lv Y, An Z, Chen H, Wang Z, Liu L. Mechanism of curcumin resistance to human cytomegalovirus in HELF cells. BMC Complement Alternat Med 2014; 14: 284.
145. Wessler S, Muenzner P, Meyer TF, Naumann M. The antiinflammatory compound curcumin inhibits Neisseria gonorrhoeaeinduced NF-kappaB signaling, release of pro-inflammatory cytokines/chemokines and attenuates adhesion in late infection. Biol Chem 2005; 386: 481-90.
146. Iranshahi M, Chini MG, Masullo M, et al. Can small chemical modifications of natural pan-inhibitors modulate the biological selectivity? The case of curcumin prenylated derivatives acting as HDAC or mPGES-1 inhibitors. J Nat Prod 2015; 78: 2867-79.
147. Kurien BT, Scofield RH. Increasing aqueous solubility of curcumin for improving bioavailability. Trends Pharmacol Sci 2009; 30: 334-5; author reply 335.
148. Peng JR, Qian ZY. Drug delivery systems for overcoming the bioavailability of curcumin: not only the nanoparticle matters. Nanomedicine (Lond) 2014; 9: 747-50.
149. Sahebkar A. The promise of curcumin-phosphatidylcholine complex for cardiometabolic diseases: more than just 'more curcumin'. Nat Prod Res 2015; 29: 392-3.
150. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 2012; 49: 580-8.
151. Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoidpiperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. Clin Nutr 2015; 34: 1101-8.
152. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res 2014; 28: 1461-7.
153. Sahebkar A. Are curcuminoids effective C-reactive proteinlowering agents in clinical practice? Evidence from a metaanalysis. Phytother Res 2014; 28: 633-42.